Johnson & Johnson Patient and Provider Support

Use the published number for the prescribed medicine. Savings, cost assistance and ongoing support have separate requirements. Contact the program for current requirements. A listed medicine does not establish eligibility, funding, coverage or enrollment.

Use the published number for the prescribed medicine. Savings, cost assistance and ongoing support have separate requirements. Contact the program for current requirements. A listed medicine does not establish eligibility, funding, coverage or enrollment.

Use the published number for the prescribed medicine. Savings, cost assistance and ongoing support have separate requirements. Contact the program for current requirements. A listed medicine does not establish eligibility, funding, coverage or enrollment.

Use the published number for the prescribed medicine. Savings, cost assistance and ongoing support have separate requirements. Contact the program for current requirements. A listed medicine does not establish eligibility, funding, coverage or enrollment.

Current STELARA withMe support and savings-resource navigation. Commercial Savings Program rebates have a separate fax/postal route. Do not infer free-medicine PAP availability: STELARA is absent from the current August 2026 J&J Patient Assistance Program guide reviewed here. Contact the program for current requirements; a listing does not establish eligibility, funding, coverage or enrollment.

Current XARELTO withMe support. The brand support number is published with matching text and tel link on the current medicine contact page. Separate J&J Patient Assistance Program eligibility questions use the PAP route. Contact the program for current requirements; a listing does not establish eligibility, funding, coverage or enrollment.

Use the published number for the prescribed medicine. Savings, cost assistance and ongoing support have separate requirements. Contact the program for current requirements. A listed medicine does not establish eligibility, funding, coverage or enrollment.

The corporate page describes the transition from Janssen CarePath to J&J withMe. Its footer update is September 26, 2024. The current patient contact page publishes medicine-specific numbers; use those when the product is known.

This is a manufacturer/distribution administrative channel, not a patient assistance application destination. The source footer says last updated September 26, 2024; confirm current routing.

The source lists adverse events, product complaints, medical and rebate questions. This is a manufacturer/distribution administrative channel, not a patient assistance application destination. The source footer says last updated September 26, 2024; confirm current routing.

This is a manufacturer/distribution administrative channel, not a patient assistance application destination. The source footer says last updated September 26, 2024; confirm current routing. This route concerns JOM invoices, not a patient insurance claim.

This is a manufacturer/distribution administrative channel, not a patient assistance application destination. The source footer says last updated September 26, 2024; confirm current routing. The source directs this return function to Inmar.

The current cost-support FAQ explicitly publishes these fax and mail destinations. This is a commercial Savings Program rebate route, not prescription intake, benefits-investigation enrollment or free-medicine patient assistance. The linked English rebate PDF returned 404; the destinations are verified directly from the current FAQ. No email or staffed fax hours are published.

The current XARELTO cost-support page links PatientAssistanceInfo.com, which redirected to the August 2026 J&J program guide. XARELTO is on that guide’s medicine list. Current income, insurance, residence and other requirements apply; the program determines eligibility. No fax or postal destination is imported from older forms. STELARA is not on this current guide’s medicine list.